Gilead maintained a Buy at Deutsche after latest data

"IMS recently released week #3 scripts for Sovaldi and our calculations indicate U.S. Q4 sales $53M," says Deutsche's Robyn Karnauskas, maintaining Gilead (GILD -1.1%) at a Buy with $95 price target. Third week new patient starts of 797 compares to 834 in week #2, with the decline likely due to Christmas. "These Sovaldi trends are very early in the launch as we just have three week of scripts."

Previous: Karnauskas after week #2.

From other sites
Comments (1)
  • JAC92651
    , contributor
    Comments (78) | Send Message
    I anticipate the ramp up will be fast and the volume will blow away analyst estimates. Long 2015 leaps.
    3 Jan 2014, 02:58 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs